Celsion Corporation (CLSN) ended last trading session with a change of -7.14 percent. It trades at an average volume of 2.21M shares versus 2.74M shares recorded at the end of last trading session. The share price of $0.26 is at a distance of 40.54 percent from its 52-week low and down -85.39 percent versus its peak. The company has a market cap of $10.12M and currently has 38.93M shares outstanding. The share price is currently 0.38 percent versus its SMA20, -19.87 percent versus its SMA50, and -71.55 percent versus its SMA200. The stock has a weekly performance of 17.12 percent and is -14.45 percent year-to-date as of the recent close.

On March 09, 2017 Celsion Corporation (CLSN) announced that the Company will host a conference call to discuss year-end 2016 financial results and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. ET on Thursday, March 16, 2017. To participate in the call, interested parties may dial 1-888-490-2763 (Toll-Free/North America) or 1-719-325-2481 (International/Toll) and ask for the Celsion Corporation 4th Quarter 2016 Earnings Call (Conference Code: 8052561) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at www.celsion.com.

Inotek Pharmaceuticals Corporation (ITEK) recently recorded 4.41 percent change and currently at $1.77 is 18.33 percent away from its 52-week low and down -83.72 percent versus its peak. It has a past 5-day performance of 14.52 percent and trades at an average volume of 1.11M shares. The stock has a 1-month performance of 7.58 percent and is -70.9 percent year-to-date as of the recent close. There were about 26.93M shares outstanding which made its market cap $47.8M. The share price is currently 11.29 percent versus its SMA20, -7.24 percent versus its SMA50, and -71.37 percent versus its SMA200.

Inotek Pharmaceuticals Corporation (ITEK) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases. The Company’s lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic currently in Phase 3 development.